Keywords
Last Name
Institution

Vahram Haroutunian

TitlePROFESSOR
InstitutionMount Sinai
DepartmentPsychiatry
Address
    Other Positions
    TitlePROFESSOR
    InstitutionMount Sinai
    DepartmentNeuroscience


     Bibliographic 
     selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Huynh JL, Garg P, Thin TH, Yoo S, Dutta R, Trapp BD, Haroutunian V, Zhu J, Donovan MJ, Sharp AJ, Casaccia P. Epigenome-wide differences in pathology-free regions of multiple sclerosis-affected brains. Nat Neurosci. 2014 Jan; 17(1):121-30.
      View in: PubMed
    2. Mamdani M, McMichael GO, Gadepalli V, Williamson V, Parker EK, Haroutunian V, Vladimirov VI. Differential regulation of schizophrenia-associated microRNA gene function by variable number tandem repeats (VNTR) polymorphism. Schizophr Res. 2013 Dec; 151(1-3):284-6.
      View in: PubMed
    3. Tucholski J, Simmons MS, Pinner AL, McMillan LD, Haroutunian V, Meador-Woodruff JH. N-linked glycosylation of cortical N-methyl-D-aspartate and kainate receptor subunits in schizophrenia. Neuroreport. 2013 Aug 21; 24(12):688-91.
      View in: PubMed
    4. Katsel P, Tan W, Fam P, Purohit DP, Haroutunian V. Cycle checkpoint abnormalities during dementia: a plausible association with the loss of protection against oxidative stress in Alzheimer's disease. PLoS One. 2013; 8(7):e68361.
      View in: PubMed
    5. Akbarian S, Beeri MS, Haroutunian V. Epigenetic determinants of healthy and diseased brain aging and cognition. JAMA Neurol. 2013 Jun; 70(6):711-8.
      View in: PubMed
    6. Rubio MD, Wood K, Haroutunian V, Meador-Woodruff JH. Dysfunction of the ubiquitin proteasome and ubiquitin-like systems in schizophrenia. Neuropsychopharmacology. 2013 Sep; 38(10):1910-20.
      View in: PubMed
    7. Drummond JB, Tucholski J, Haroutunian V, Meador-Woodruff JH. Transmembrane AMPA receptor regulatory protein (TARP) dysregulation in anterior cingulate cortex in schizophrenia. Schizophr Res. 2013 Jun; 147(1):32-8.
      View in: PubMed
    8. Gandy S, Haroutunian V, DeKosky ST, Sano M, Schadt EE. CR1 and the "vanishing amyloid" hypothesis of Alzheimer's disease. Biol Psychiatry. 2013 Mar 1; 73(5):393-5.
      View in: PubMed
    9. Tucholski J, Simmons MS, Pinner AL, Haroutunian V, McCullumsmith RE, Meador-Woodruff JH. Abnormal N-linked glycosylation of cortical AMPA receptor subunits in schizophrenia. Schizophr Res. 2013 May; 146(1-3):177-83.
      View in: PubMed
    10. Shan D, Lucas EK, Drummond JB, Haroutunian V, Meador-Woodruff JH, McCullumsmith RE. Abnormal expression of glutamate transporters in temporal lobe areas in elderly patients with schizophrenia. Schizophr Res. 2013 Mar; 144(1-3):1-8.
      View in: PubMed
    11. Zhao W, Ho L, Varghese M, Yemul S, Dams-O'Connor K, Gordon W, Knable L, Freire D, Haroutunian V, Pasinetti GM. Decreased level of olfactory receptors in blood cells following traumatic brain injury and potential association with tauopathy. J Alzheimers Dis. 2013 Jan 1; 34(2):417-29.
      View in: PubMed
    12. Drummond JB, Simmons M, Haroutunian V, Meador-Woodruff JH. Upregulation of cornichon transcripts in the dorsolateral prefrontal cortex in schizophrenia. Neuroreport. 2012 Dec 5; 23(17):1031-4.
      View in: PubMed
    13. Roussos P, Katsel P, Davis KL, Siever LJ, Haroutunian V. A system-level transcriptomic analysis of schizophrenia using postmortem brain tissue samples. Arch Gen Psychiatry. 2012 Dec; 69(12):1205-13.
      View in: PubMed
    14. Roussos P, Katsel P, Davis KL, Giakoumaki SG, Lencz T, Malhotra AK, Siever LJ, Bitsios P, Haroutunian V. Convergent findings for abnormalities of the NF-?B signaling pathway in schizophrenia. Neuropsychopharmacology. 2013 Feb; 38(3):533-9.
      View in: PubMed
    15. Silverman JM, Schmeidler J, Beeri MS, Rosendorff C, Sano M, Grossman HT, Carrión-Baralt JR, Bespalova IN, West R, Haroutunian V. C-reactive protein and familial risk for dementia: a phenotype for successful cognitive aging. Neurology. 2012 Sep 11; 79(11):1116-23.
      View in: PubMed
    16. Hallacoglu B, Sassaroli A, Wysocki M, Guerrero-Berroa E, Schnaider Beeri M, Haroutunian V, Shaul M, Rosenberg IH, Troen AM, Fantini S. Absolute measurement of cerebral optical coefficients, hemoglobin concentration and oxygen saturation in old and young adults with near-infrared spectroscopy. J Biomed Opt. 2012 Aug; 17(8):081406-1.
      View in: PubMed
    17. Carty NC, Xu J, Kurup P, Brouillette J, Goebel-Goody SM, Austin DR, Yuan P, Chen G, Correa PR, Haroutunian V, Pittenger C, Lombroso PJ. The tyrosine phosphatase STEP: implications in schizophrenia and the molecular mechanism underlying antipsychotic medications. Transl Psychiatry. 2012; 2:e137.
      View in: PubMed
    18. Hammond JC, Meador-Woodruff JH, Haroutunian V, McCullumsmith RE. AMPA receptor subunit expression in the endoplasmic reticulum in frontal cortex of elderly patients with schizophrenia. PLoS One. 2012; 7(6):e39190.
      View in: PubMed
    19. Ho L, Yemul S, Knable L, Katsel P, Zhao R, Haroutunian V, Pasinetti GM. Insulin receptor expression and activity in the brains of nondiabetic sporadic Alzheimer's disease cases. Int J Alzheimers Dis. 2012; 2012:321280.
      View in: PubMed
    20. Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ, Castellani RJ, Crain BJ, Davies P, Del Tredici K, Duyckaerts C, Frosch MP, Haroutunian V, Hof PR, Hulette CM, Hyman BT, Iwatsubo T, Jellinger KA, Jicha GA, Kövari E, Kukull WA, Leverenz JB, Love S, Mackenzie IR, Mann DM, Masliah E, McKee AC, Montine TJ, Morris JC, Schneider JA, Sonnen JA, Thal DR, Trojanowski JQ, Troncoso JC, Wisniewski T, Woltjer RL, Beach TG. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol. 2012 May; 71(5):362-81.
      View in: PubMed
    21. Rubio MD, Haroutunian V, Meador-Woodruff JH. Abnormalities of the Duo/Ras-related C3 botulinum toxin substrate 1/p21-activated kinase 1 pathway drive myosin light chain phosphorylation in frontal cortex in schizophrenia. Biol Psychiatry. 2012 May 15; 71(10):906-14.
      View in: PubMed
    22. Shan D, Haroutunian V, Meador-Woodruff JH, McCullumsmith RE. Expression of equilibrative nucleoside transporter type 1 protein in elderly patients with schizophrenia. Neuroreport. 2012 Mar 7; 23(4):224-7.
      View in: PubMed
    23. Wysocki M, Luo X, Schmeidler J, Dahlman K, Lesser GT, Grossman H, Haroutunian V, Beeri MS. Hypertension is associated with cognitive decline in elderly people at high risk for dementia. Am J Geriatr Psychiatry. 2012 Feb; 20(2):179-87.
      View in: PubMed
    24. Moehle MS, Luduena RF, Haroutunian V, Meador-Woodruff JH, McCullumsmith RE. Regional differences in expression of ß-tubulin isoforms in schizophrenia. Schizophr Res. 2012 Mar; 135(1-3):181-6.
      View in: PubMed
    25. Ho L, Zhao W, Dams-O'Connor K, Tang CY, Gordon W, Peskind ER, Yemul S, Haroutunian V, Pasinetti GM. Elevated plasma MCP-1 concentration following traumatic brain injury as a potential "predisposition" factor associated with an increased risk for subsequent development of Alzheimer's disease. J Alzheimers Dis. 2012; 31(2):301-13.
      View in: PubMed
    26. Ravona-Springer R, Moshier E, Schmeidler J, Godbold J, Akrivos J, Rapp M, Grossman HT, Wysocki M, Silverman JM, Haroutunian V, Beeri MS. Changes in glycemic control are associated with changes in cognition in non-diabetic elderly. J Alzheimers Dis. 2012; 30(2):299-309.
      View in: PubMed
    27. Beeri MS, Haroutunian V, Schmeidler J, Sano M, Fam P, Kavanaugh A, Barr AM, Honer WG, Katsel P. Synaptic protein deficits are associated with dementia irrespective of extreme old age. Neurobiol Aging. 2012 Jun; 33(6):1125.e1-8.
      View in: PubMed
    28. Funk AJ, McCullumsmith RE, Haroutunian V, Meador-Woodruff JH. Abnormal activity of the MAPK- and cAMP-associated signaling pathways in frontal cortical areas in postmortem brain in schizophrenia. Neuropsychopharmacology. 2012 Mar; 37(4):896-905.
      View in: PubMed
    29. Ravona-Springer R, Luo X, Schmeidler J, Wysocki M, Lesser GT, Rapp MA, Dahlman K, Grossman HT, Haroutunian V, Beeri MS. The association of age with rate of cognitive decline in elderly individuals residing in supporting care facilities. Alzheimer Dis Assoc Disord. 2011 Oct-Dec; 25(4):312-6.
      View in: PubMed
    30. Xu H, Haroutunian V, Bartzokis G, Shenton ME. Oligodendrocytes in schizophrenia. Schizophr Res Treatment. 2011; 2011:249768.
      View in: PubMed
    31. Roussos P, Katsel P, Davis KL, Bitsios P, Giakoumaki SG, Jogia J, Rozsnyai K, Collier D, Frangou S, Siever LJ, Haroutunian V. Molecular and genetic evidence for abnormalities in the nodes of Ranvier in schizophrenia. Arch Gen Psychiatry. 2012 Jan; 69(1):7-15.
      View in: PubMed
    32. Akram A, Schmeidler J, Katsel P, Hof PR, Haroutunian V. Association of ApoE and LRP mRNA levels with dementia and AD neuropathology. Neurobiol Aging. 2012 Mar; 33(3):628.e1-628.e14.
      View in: PubMed
    33. Katsel P, Tan W, Abazyan B, Davis KL, Ross C, Pletnikov MV, Haroutunian V. Expression of mutant human DISC1 in mice supports abnormalities in differentiation of oligodendrocytes. Schizophr Res. 2011 Aug; 130(1-3):238-49.
      View in: PubMed
    34. Hammond JC, McCullumsmith RE, Haroutunian V, Meador-Woodruff JH. Endosomal trafficking of AMPA receptors in frontal cortex of elderly patients with schizophrenia. Schizophr Res. 2011 Aug; 130(1-3):260-5.
      View in: PubMed
    35. Sodhi MS, Simmons M, McCullumsmith R, Haroutunian V, Meador-Woodruff JH. Glutamatergic gene expression is specifically reduced in thalamocortical projecting relay neurons in schizophrenia. Biol Psychiatry. 2011 Oct 1; 70(7):646-54.
      View in: PubMed
    36. Lesser GT, Beeri MS, Schmeidler J, Purohit DP, Haroutunian V. Cholesterol and LDL relate to neuritic plaques and to APOE4 presence but not to neurofibrillary tangles. Curr Alzheimer Res. 2011 May; 8(3):303-12.
      View in: PubMed
    37. Beeri MS, Schmeidler J, Lesser GT, Maroukian M, West R, Leung S, Wysocki M, Perl DP, Purohit DP, Haroutunian V. Corticosteroids, but not NSAIDs, are associated with less Alzheimer neuropathology. Neurobiol Aging. 2012 Jul; 33(7):1258-64.
      View in: PubMed
    38. Rapp MA, Schnaider-Beeri M, Wysocki M, Guerrero-Berroa E, Grossman HT, Heinz A, Haroutunian V. Cognitive decline in patients with dementia as a function of depression. Am J Geriatr Psychiatry. 2011 Apr; 19(4):357-63.
      View in: PubMed
    39. Horesh Y, Katsel P, Haroutunian V, Domany E. Gene expression signature is shared by patients with Alzheimer's disease and schizophrenia at the superior temporal gyrus. Eur J Neurol. 2011 Mar; 18(3):410-24.
      View in: PubMed
    40. Katsel P, Byne W, Roussos P, Tan W, Siever L, Haroutunian V. Astrocyte and glutamate markers in the superficial, deep, and white matter layers of the anterior cingulate gyrus in schizophrenia. Neuropsychopharmacology. 2011 May; 36(6):1171-7.
      View in: PubMed
    41. Radu A, Hristescu G, Katsel P, Haroutunian V, Davis KL. Microarray database mining and cell differentiation defects in schizophrenia. Adv Exp Med Biol. 2011; 696:67-74.
      View in: PubMed
    42. Lyddon R, Cuppen E, Haroutunian V, Siever LJ, Dracheva S. No link of serotonin 2C receptor editing to serotonin transporter genotype. Neuroreport. 2010 Dec 8; 21(17):1080-4.
      View in: PubMed
    43. Gong B, Chen F, Pan Y, Arrieta-Cruz I, Yoshida Y, Haroutunian V, Pasinetti GM. SCFFbx2-E3-ligase-mediated degradation of BACE1 attenuates Alzheimer's disease amyloidosis and improves synaptic function. Aging Cell. 2010 Dec; 9(6):1018-31.
      View in: PubMed
    44. Naj AC, Beecham GW, Martin ER, Gallins PJ, Powell EH, Konidari I, Whitehead PL, Cai G, Haroutunian V, Scott WK, Vance JM, Slifer MA, Gwirtsman HE, Gilbert JR, Haines JL, Buxbaum JD, Pericak-Vance MA. Dementia revealed: novel chromosome 6 locus for late-onset Alzheimer disease provides genetic evidence for folate-pathway abnormalities. PLoS Genet. 2010 Sep; 6(9):e1001130.
      View in: PubMed
    45. Min SW, Cho SH, Zhou Y, Schroeder S, Haroutunian V, Seeley WW, Huang EJ, Shen Y, Masliah E, Mukherjee C, Meyers D, Cole PA, Ott M, Gan L. Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron. 2010 Sep 23; 67(6):953-66.
      View in: PubMed
    46. Akram A, Schmeidler J, Katsel P, Hof PR, Haroutunian V. Increased expression of RXRa in dementia: an early harbinger for the cholesterol dyshomeostasis? Mol Neurodegener. 2010; 5:36.
      View in: PubMed
    47. Deep-Soboslay A, Benes FM, Haroutunian V, Ellis JK, Kleinman JE, Hyde TM. Psychiatric brain banking: three perspectives on current trends and future directions. Biol Psychiatry. 2011 Jan 15; 69(2):104-12.
      View in: PubMed
    48. Kristiansen LV, Patel SA, Haroutunian V, Meador-Woodruff JH. Expression of the NR2B-NMDA receptor subunit and its Tbr-1/CINAP regulatory proteins in postmortem brain suggest altered receptor processing in schizophrenia. Synapse. 2010 Jul; 64(7):495-502.
      View in: PubMed
    49. Hammond JC, McCullumsmith RE, Funk AJ, Haroutunian V, Meador-Woodruff JH. Evidence for abnormal forward trafficking of AMPA receptors in frontal cortex of elderly patients with schizophrenia. Neuropsychopharmacology. 2010 Sep; 35(10):2110-9.
      View in: PubMed
    50. Kerns D, Vong GS, Barley K, Dracheva S, Katsel P, Casaccia P, Haroutunian V, Byne W. Gene expression abnormalities and oligodendrocyte deficits in the internal capsule in schizophrenia. Schizophr Res. 2010 Jul; 120(1-3):150-8.
      View in: PubMed
    51. Kurup P, Zhang Y, Xu J, Venkitaramani DV, Haroutunian V, Greengard P, Nairn AC, Lombroso PJ. Abeta-mediated NMDA receptor endocytosis in Alzheimer's disease involves ubiquitination of the tyrosine phosphatase STEP61. J Neurosci. 2010 Apr 28; 30(17):5948-57.
      View in: PubMed
    52. Kristiansen LV, Bakir B, Haroutunian V, Meador-Woodruff JH. Expression of the NR2B-NMDA receptor trafficking complex in prefrontal cortex from a group of elderly patients with schizophrenia. Schizophr Res. 2010 Jun; 119(1-3):198-209.
      View in: PubMed
    53. Ravona-Springer R, Luo X, Schmeidler J, Wysocki M, Lesser G, Rapp M, Dahlman K, Grossman H, Haroutunian V, Schnaider Beeri M. Diabetes is associated with increased rate of cognitive decline in questionably demented elderly. Dement Geriatr Cogn Disord. 2010; 29(1):68-74.
      View in: PubMed
    54. Akram A, Schmeidler J, Katsel P, Hof PR, Haroutunian V. Increased expression of cholesterol transporter ABCA1 is highly correlated with severity of dementia in AD hippocampus. Brain Res. 2010 Mar 8; 1318:167-77.
      View in: PubMed
    55. Kajiwara Y, Franciosi S, Takahashi N, Krug L, Schmeidler J, Taddei K, Haroutunian V, Fried U, Ehrlich M, Martins RN, Gandy S, Buxbaum JD. Extensive proteomic screening identifies the obesity-related NYGGF4 protein as a novel LRP1-interactor, showing reduced expression in early Alzheimer's disease. Mol Neurodegener. 2010; 5:1.
      View in: PubMed
    56. Rapp MA, Schnaider-Beeri M, Purohit DP, Reichenberg A, McGurk SR, Haroutunian V, Harvey PD. Cortical neuritic plaques and hippocampal neurofibrillary tangles are related to dementia severity in elderly schizophrenia patients. Schizophr Res. 2010 Jan; 116(1):90-6.
      View in: PubMed
    57. Guerrero-Berroa E, Luo X, Schmeidler J, Rapp MA, Dahlman K, Grossman HT, Haroutunian V, Beeri MS. The MMSE orientation for time domain is a strong predictor of subsequent cognitive decline in the elderly. Int J Geriatr Psychiatry. 2009 Dec; 24(12):1429-37.
      View in: PubMed
    58. Katsel P, Tan W, Haroutunian V. Gain in brain immunity in the oldest-old differentiates cognitively normal from demented individuals. PLoS One. 2009; 4(10):e7642.
      View in: PubMed
    59. Beeri MS, Schmeidler J, Haroutunian V, West R, Ostad D, Grossman HT, Rosendorff C, Silverman JM. Better cognitive performance associated with worse cardiac functioning suggests antagonistic pleiotropy in very elderly subjects. Am J Geriatr Psychiatry. 2009 Oct; 17(10):911-2.
      View in: PubMed
    60. Bauer D, Haroutunian V, Meador-Woodruff JH, McCullumsmith RE. Abnormal glycosylation of EAAT1 and EAAT2 in prefrontal cortex of elderly patients with schizophrenia. Schizophr Res. 2010 Mar; 117(1):92-8.
      View in: PubMed
    61. Libow LS, Frisina PG, Haroutunian V, Perl DP, Purohit DP. Parkinson's disease dementia: a diminished role for the Lewy body. Parkinsonism Relat Disord. 2009 Sep; 15(8):572-5.
      View in: PubMed
    62. Kajiwara Y, Akram A, Katsel P, Haroutunian V, Schmeidler J, Beecham G, Haines JL, Pericak-Vance MA, Buxbaum JD. FE65 binds Teashirt, inhibiting expression of the primate-specific caspase-4. PLoS One. 2009; 4(4):e5071.
      View in: PubMed
    63. Qin W, Haroutunian V, Katsel P, Cardozo CP, Ho L, Buxbaum JD, Pasinetti GM. PGC-1alpha expression decreases in the Alzheimer disease brain as a function of dementia. Arch Neurol. 2009 Mar; 66(3):352-61.
      View in: PubMed
    64. Hoffman LB, Schmeidler J, Lesser GT, Beeri MS, Purohit DP, Grossman HT, Haroutunian V. Less Alzheimer disease neuropathology in medicated hypertensive than nonhypertensive persons. Neurology. 2009 May 19; 72(20):1720-6.
      View in: PubMed
    65. Bauer DE, Haroutunian V, McCullumsmith RE, Meador-Woodruff JH. Expression of four housekeeping proteins in elderly patients with schizophrenia. J Neural Transm. 2009 Apr; 116(4):487-91.
      View in: PubMed
    66. Lesser GT, Haroutunian V, Purohit DP, Schnaider Beeri M, Schmeidler J, Honkanen L, Neufeld R, Libow LS. Serum lipids are related to Alzheimer's pathology in nursing home residents. Dement Geriatr Cogn Disord. 2009; 27(1):42-9.
      View in: PubMed
    67. Haroutunian V, Hoffman LB, Beeri MS. Is there a neuropathology difference between mild cognitive impairment and dementia? Dialogues Clin Neurosci. 2009; 11(2):171-9.
      View in: PubMed
    68. Amadio M, Pascale A, Wang J, Ho L, Quattrone A, Gandy S, Haroutunian V, Racchi M, Pasinetti GM. nELAV proteins alteration in Alzheimer's disease brain: a novel putative target for amyloid-beta reverberating on AbetaPP processing. J Alzheimers Dis. 2009; 16(2):409-19.
      View in: PubMed
    69. Beeri MS, Ravona-Springer R, Silverman JM, Haroutunian V. The effects of cardiovascular risk factors on cognitive compromise. Dialogues Clin Neurosci. 2009; 11(2):201-12.
      View in: PubMed
    70. Rao MV, Mohan PS, Peterhoff CM, Yang DS, Schmidt SD, Stavrides PH, Campbell J, Chen Y, Jiang Y, Paskevich PA, Cataldo AM, Haroutunian V, Nixon RA. Marked calpastatin (CAST) depletion in Alzheimer's disease accelerates cytoskeleton disruption and neurodegeneration: neuroprotection by CAST overexpression. J Neurosci. 2008 Nov 19; 28(47):12241-54.
      View in: PubMed
    71. Alelú-Paz R, Iturrieta-Zuazo I, Byne W, Haroutunian V, García-Villanueva M, Rábano A, García-Amado M, Prensa L, Giménez-Amaya JM. A new antigen retrieval technique for human brain tissue. PLoS One. 2008; 3(10):e3378.
      View in: PubMed
    72. Beeri MS, Schmeidler J, Silverman JM, Gandy S, Wysocki M, Hannigan CM, Purohit DP, Lesser G, Grossman HT, Haroutunian V. Insulin in combination with other diabetes medication is associated with less Alzheimer neuropathology. Neurology. 2008 Sep 2; 71(10):750-7.
      View in: PubMed
    73. Haroutunian V, Schnaider-Beeri M, Schmeidler J, Wysocki M, Purohit DP, Perl DP, Libow LS, Lesser GT, Maroukian M, Grossman HT. Role of the neuropathology of Alzheimer disease in dementia in the oldest-old. Arch Neurol. 2008 Sep; 65(9):1211-7.
      View in: PubMed
    74. Frisina PG, Haroutunian V, Libow LS. The neuropathological basis for depression in Parkinson's disease. Parkinsonism Relat Disord. 2009 Feb; 15(2):144-8.
      View in: PubMed
    75. Steffek AE, McCullumsmith RE, Haroutunian V, Meador-Woodruff JH. Cortical expression of glial fibrillary acidic protein and glutamine synthetase is decreased in schizophrenia. Schizophr Res. 2008 Aug; 103(1-3):71-82.
      View in: PubMed
    76. Elder GA, Ragnauth A, Dorr N, Franciosi S, Schmeidler J, Haroutunian V, Buxbaum JD. Increased locomotor activity in mice lacking the low-density lipoprotein receptor. Behav Brain Res. 2008 Aug 22; 191(2):256-65.
      View in: PubMed
    77. Dracheva S, Byne W, Chin B, Haroutunian V. Ionotropic glutamate receptor mRNA expression in the human thalamus: absence of change in schizophrenia. Brain Res. 2008 Jun 12; 1214:23-34.
      View in: PubMed
    78. Schnaider Beeri M, Silverman JM, Schmeidler J, Wysocki M, Grossman HZ, Purohit DP, Perl DP, Haroutunian V. Clinical dementia rating performed several years prior to death predicts regional Alzheimer's neuropathology. Dement Geriatr Cogn Disord. 2008; 25(5):392-8.
      View in: PubMed
    79. Katsel P, Davis KL, Li C, Tan W, Greenstein E, Kleiner Hoffman LB, Haroutunian V. Abnormal indices of cell cycle activity in schizophrenia and their potential association with oligodendrocytes. Neuropsychopharmacology. 2008 Nov; 33(12):2993-3009.
      View in: PubMed
    80. Lauriat TL, Shiue L, Haroutunian V, Verbitsky M, Ares M, Ospina L, McInnes LA. Developmental expression profile of quaking, a candidate gene for schizophrenia, and its target genes in human prefrontal cortex and hippocampus shows regional specificity. J Neurosci Res. 2008 Mar; 86(4):785-96.
      View in: PubMed
    81. Dracheva S, Chin B, Haroutunian V. Altered serotonin 2C receptor RNA splicing in suicide: association with editing. Neuroreport. 2008 Feb 12; 19(3):379-82.
      View in: PubMed
    82. Rapp MA, Schnaider-Beeri M, Purohit DP, Perl DP, Haroutunian V, Sano M. Increased neurofibrillary tangles in patients with Alzheimer disease with comorbid depression. Am J Geriatr Psychiatry. 2008 Feb; 16(2):168-74.
      View in: PubMed
    83. Beeri MS, Rapp M, Schmeidler J, Reichenberg A, Purohit DP, Perl DP, Grossman HT, Prohovnik I, Haroutunian V, Silverman JM. Number of children is associated with neuropathology of Alzheimer's disease in women. Neurobiol Aging. 2009 Aug; 30(8):1184-91.
      View in: PubMed
    84. Oni-Orisan A, Kristiansen LV, Haroutunian V, Meador-Woodruff JH, McCullumsmith RE. Altered vesicular glutamate transporter expression in the anterior cingulate cortex in schizophrenia. Biol Psychiatry. 2008 Apr 15; 63(8):766-75.
      View in: PubMed
    85. Byne W, Dracheva S, Chin B, Schmeidler JM, Davis KL, Haroutunian V. Schizophrenia and sex associated differences in the expression of neuronal and oligodendrocyte-specific genes in individual thalamic nuclei. Schizophr Res. 2008 Jan; 98(1-3):118-28.
      View in: PubMed
    86. Haroutunian V, Pickett J. Autism brain tissue banking. Brain Pathol. 2007 Oct; 17(4):412-21.
      View in: PubMed
    87. Haroutunian V, Katsel P, Schmeidler J. Transcriptional vulnerability of brain regions in Alzheimer's disease and dementia. Neurobiol Aging. 2009 Apr; 30(4):561-73.
      View in: PubMed
    88. Dracheva S, Patel N, Woo DA, Marcus SM, Siever LJ, Haroutunian V. Increased serotonin 2C receptor mRNA editing: a possible risk factor for suicide. Mol Psychiatry. 2008 Nov; 13(11):1001-10.
      View in: PubMed
    89. Baker DA, Madayag A, Kristiansen LV, Meador-Woodruff JH, Haroutunian V, Raju I. Contribution of cystine-glutamate antiporters to the psychotomimetic effects of phencyclidine. Neuropsychopharmacology. 2008 Jun; 33(7):1760-72.
      View in: PubMed
    90. Haroutunian V, Davis KL. Introduction to the special section: Myelin and oligodendrocyte abnormalities in schizophrenia. Int J Neuropsychopharmacol. 2007 Aug; 10(4):499-502.
      View in: PubMed
    91. Elder GA, Cho JY, English DF, Franciosi S, Schmeidler J, Sosa MA, Gasperi RD, Fisher EA, Mathews PM, Haroutunian V, Buxbaum JD. Elevated plasma cholesterol does not affect brain Abeta in mice lacking the low-density lipoprotein receptor. J Neurochem. 2007 Aug; 102(4):1220-31.
      View in: PubMed
    92. Akram A, Christoffel D, Rocher AB, Bouras C, Kövari E, Perl DP, Morrison JH, Herrmann FR, Haroutunian V, Giannakopoulos P, Hof PR. Stereologic estimates of total spinophilin-immunoreactive spine number in area 9 and the CA1 field: relationship with the progression of Alzheimer's disease. Neurobiol Aging. 2008 Sep; 29(9):1296-307.
      View in: PubMed
    93. Katsel P, Li C, Haroutunian V. Gene expression alterations in the sphingolipid metabolism pathways during progression of dementia and Alzheimer's disease: a shift toward ceramide accumulation at the earliest recognizable stages of Alzheimer's disease? Neurochem Res. 2007 Apr-May; 32(4-5):845-56.
      View in: PubMed
    94. Haroutunian V, Katsel P, Dracheva S, Stewart DG, Davis KL. Variations in oligodendrocyte-related gene expression across multiple cortical regions: implications for the pathophysiology of schizophrenia. Int J Neuropsychopharmacol. 2007 Aug; 10(4):565-73.
      View in: PubMed
    95. Greenstein RJ, Su L, Haroutunian V, Shahidi A, Brown ST. On the action of methotrexate and 6-mercaptopurine on M. avium subspecies paratuberculosis. PLoS One. 2007; 2(1):e161.
      View in: PubMed
    96. McCullumsmith RE, Gupta D, Beneyto M, Kreger E, Haroutunian V, Davis KL, Meador-Woodruff JH. Expression of transcripts for myelination-related genes in the anterior cingulate cortex in schizophrenia. Schizophr Res. 2007 Feb; 90(1-3):15-27.
      View in: PubMed
    97. Haroutunian V, Katsel P, Dracheva S, Davis KL. The human homolog of the QKI gene affected in the severe dysmyelination "quaking" mouse phenotype: downregulated in multiple brain regions in schizophrenia. Am J Psychiatry. 2006 Oct; 163(10):1834-7.
      View in: PubMed
    98. Lauriat TL, Dracheva S, Kremerskothen J, Duning K, Haroutunian V, Buxbaum JD, Hyde TM, Kleinman JE, McInnes LA. Characterization of KIAA0513, a novel signaling molecule that interacts with modulators of neuroplasticity, apoptosis, and the cytoskeleton. Brain Res. 2006 Nov 22; 1121(1):1-11.
      View in: PubMed
    99. Baracskay KL, Haroutunian V, Meador-Woodruff JH. Dopamine receptor signaling molecules are altered in elderly schizophrenic cortex. Synapse. 2006 Sep 15; 60(4):271-9.
      View in: PubMed
    100. Yakovleva T, Marinova Z, Kuzmin A, Seidah NG, Haroutunian V, Terenius L, Bakalkin G. Dysregulation of dynorphins in Alzheimer disease. Neurobiol Aging. 2007 Nov; 28(11):1700-8.
      View in: PubMed
    101. Georgieva L, Moskvina V, Peirce T, Norton N, Bray NJ, Jones L, Holmans P, Macgregor S, Zammit S, Wilkinson J, Williams H, Nikolov I, Williams N, Ivanov D, Davis KL, Haroutunian V, Buxbaum JD, Craddock N, Kirov G, Owen MJ, O'Donovan MC. Convergent evidence that oligodendrocyte lineage transcription factor 2 (OLIG2) and interacting genes influence susceptibility to schizophrenia. Proc Natl Acad Sci U S A. 2006 Aug 15; 103(33):12469-74.
      View in: PubMed
    102. Steffek AE, Haroutunian V, Meador-Woodruff JH. Serine racemase protein expression in cortex and hippocampus in schizophrenia. Neuroreport. 2006 Jul 31; 17(11):1181-5.
      View in: PubMed
    103. Religa D, Strozyk D, Cherny RA, Volitakis I, Haroutunian V, Winblad B, Naslund J, Bush AI. Elevated cortical zinc in Alzheimer disease. Neurology. 2006 Jul 11; 67(1):69-75.
      View in: PubMed
    104. Gill SK, Ishak M, Dobransky T, Haroutunian V, Davis KL, Rylett RJ. 82-kDa choline acetyltransferase is in nuclei of cholinergic neurons in human CNS and altered in aging and Alzheimer disease. Neurobiol Aging. 2007 Jul; 28(7):1028-40.
      View in: PubMed
    105. Zhao Z, Xiang Z, Haroutunian V, Buxbaum JD, Stetka B, Pasinetti GM. Insulin degrading enzyme activity selectively decreases in the hippocampal formation of cases at high risk to develop Alzheimer's disease. Neurobiol Aging. 2007 Jun; 28(6):824-30.
      View in: PubMed
    106. Clinton SM, Haroutunian V, Meador-Woodruff JH. Up-regulation of NMDA receptor subunit and post-synaptic density protein expression in the thalamus of elderly patients with schizophrenia. J Neurochem. 2006 Aug; 98(4):1114-25.
      View in: PubMed
    107. Huerta I, McCullumsmith RE, Haroutunian V, Giménez-Amaya JM, Meador-Woodruff JH. Expression of excitatory amino acid transporter interacting protein transcripts in the thalamus in schizophrenia. Synapse. 2006 Jun 1; 59(7):394-402.
      View in: PubMed
    108. Byne W, Kidkardnee S, Tatusov A, Yiannoulos G, Buchsbaum MS, Haroutunian V. Schizophrenia-associated reduction of neuronal and oligodendrocyte numbers in the anterior principal thalamic nucleus. Schizophr Res. 2006 Jul; 85(1-3):245-53.
      View in: PubMed
    109. Kristiansen LV, Beneyto M, Haroutunian V, Meador-Woodruff JH. Changes in NMDA receptor subunits and interacting PSD proteins in dorsolateral prefrontal and anterior cingulate cortex indicate abnormal regional expression in schizophrenia. Mol Psychiatry. 2006 Aug; 11(8):737-47, 705.
      View in: PubMed
    110. Beeri MS, Rapp M, Silverman JM, Schmeidler J, Grossman HT, Fallon JT, Purohit DP, Perl DP, Siddiqui A, Lesser G, Rosendorff C, Haroutunian V. Coronary artery disease is associated with Alzheimer disease neuropathology in APOE4 carriers. Neurology. 2006 May 9; 66(9):1399-404.
      View in: PubMed
    111. Zhao Z, Ksiezak-Reding H, Riggio S, Haroutunian V, Pasinetti GM. Insulin receptor deficits in schizophrenia and in cellular and animal models of insulin receptor dysfunction. Schizophr Res. 2006 May; 84(1):1-14.
      View in: PubMed
    112. Rapp MA, Schnaider-Beeri M, Grossman HT, Sano M, Perl DP, Purohit DP, Gorman JM, Haroutunian V. Increased hippocampal plaques and tangles in patients with Alzheimer disease with a lifetime history of major depression. Arch Gen Psychiatry. 2006 Feb; 63(2):161-7.
      View in: PubMed
    113. Prohovnik I, Perl DP, Davis KL, Libow L, Lesser G, Haroutunian V. Dissociation of neuropathology from severity of dementia in late-onset Alzheimer disease. Neurology. 2006 Jan 10; 66(1):49-55.
      View in: PubMed
    114. Xiang Z, Haroutunian V, Ho L, Purohit D, Pasinetti GM. Microglia activation in the brain as inflammatory biomarker of Alzheimer's disease neuropathology and clinical dementia. Dis Markers. 2006; 22(1-2):95-102.
      View in: PubMed
    115. Peirce TR, Bray NJ, Williams NM, Norton N, Moskvina V, Preece A, Haroutunian V, Buxbaum JD, Owen MJ, O'Donovan MC. Convergent evidence for 2',3'-cyclic nucleotide 3'-phosphodiesterase as a possible susceptibility gene for schizophrenia. Arch Gen Psychiatry. 2006 Jan; 63(1):18-24.
      View in: PubMed
    116. Haroutunian V, Davies P, Vianna C, Buxbaum JD, Purohit DP. Tau protein abnormalities associated with the progression of alzheimer disease type dementia. Neurobiol Aging. 2007 Jan; 28(1):1-7.
      View in: PubMed
    117. Lauriat TL, Dracheva S, Chin B, Schmeidler J, McInnes LA, Haroutunian V. Quantitative analysis of glutamate transporter mRNA expression in prefrontal and primary visual cortex in normal and schizophrenic brain. Neuroscience. 2006 Feb; 137(3):843-51.
      View in: PubMed
    118. Dracheva S, Davis KL, Chin B, Woo DA, Schmeidler J, Haroutunian V. Myelin-associated mRNA and protein expression deficits in the anterior cingulate cortex and hippocampus in elderly schizophrenia patients. Neurobiol Dis. 2006 Mar; 21(3):531-40.
      View in: PubMed
    119. Clinton SM, Ibrahim HM, Frey KA, Davis KL, Haroutunian V, Meador-Woodruff JH. Dopaminergic abnormalities in select thalamic nuclei in schizophrenia: involvement of the intracellular signal integrating proteins calcyon and spinophilin. Am J Psychiatry. 2005 Oct; 162(10):1859-71.
      View in: PubMed
    120. Zhao Z, Ho L, Wang J, Qin W, Festa ED, Mobbs C, Hof P, Rocher A, Masur S, Haroutunian V, Pasinetti GM. Connective tissue growth factor (CTGF) expression in the brain is a downstream effector of insulin resistance- associated promotion of Alzheimer's disease beta-amyloid neuropathology. FASEB J. 2005 Dec; 19(14):2081-2.
      View in: PubMed
    121. Katsel P, Davis KL, Gorman JM, Haroutunian V. Variations in differential gene expression patterns across multiple brain regions in schizophrenia. Schizophr Res. 2005 Sep 15; 77(2-3):241-52.
      View in: PubMed
    122. Katsel P, Davis KL, Haroutunian V. Variations in myelin and oligodendrocyte-related gene expression across multiple brain regions in schizophrenia: a gene ontology study. Schizophr Res. 2005 Nov 15; 79(2-3):157-73.
      View in: PubMed
    123. Gupta DS, McCullumsmith RE, Beneyto M, Haroutunian V, Davis KL, Meador-Woodruff JH. Metabotropic glutamate receptor protein expression in the prefrontal cortex and striatum in schizophrenia. Synapse. 2005 Sep 1; 57(3):123-31.
      View in: PubMed
    124. Bruneau EG, McCullumsmith RE, Haroutunian V, Davis KL, Meador-Woodruff JH. Increased expression of glutaminase and glutamine synthetase mRNA in the thalamus in schizophrenia. Schizophr Res. 2005 Jun 1; 75(1):27-34.
      View in: PubMed
    125. Rapp MA, Schnaider Beeri M, Schmeidler J, Sano M, Silverman JM, Haroutunian V. Relationship of neuropsychological performance to functional status in nursing home residents and community-dwelling older adults. Am J Geriatr Psychiatry. 2005 Jun; 13(6):450-9.
      View in: PubMed
    126. Rapp MA, Schnaider-Beeri M, Sano M, Silverman JM, Haroutunian V. Cross-domain variability of cognitive performance in very old nursing home residents and community dwellers: relationship to functional status. Gerontology. 2005 May-Jun; 51(3):206-12.
      View in: PubMed
    127. Bubber P, Haroutunian V, Fisch G, Blass JP, Gibson GE. Mitochondrial abnormalities in Alzheimer brain: mechanistic implications. Ann Neurol. 2005 May; 57(5):695-703.
      View in: PubMed
    128. Rapp MA, Dahlman K, Sano M, Grossman HT, Haroutunian V, Gorman JM. Neuropsychological differences between late-onset and recurrent geriatric major depression. Am J Psychiatry. 2005 Apr; 162(4):691-8.
      View in: PubMed
    129. Beeri MS, Silverman JM, Davis KL, Marin D, Grossman HZ, Schmeidler J, Purohit DP, Perl DP, Davidson M, Mohs RC, Haroutunian V. Type 2 diabetes is negatively associated with Alzheimer's disease neuropathology. J Gerontol A Biol Sci Med Sci. 2005 Apr; 60(4):471-5.
      View in: PubMed
    130. Dracheva S, McGurk SR, Haroutunian V. mRNA expression of AMPA receptors and AMPA receptor binding proteins in the cerebral cortex of elderly schizophrenics. J Neurosci Res. 2005 Mar 15; 79(6):868-78.
      View in: PubMed
    131. Katsel PL, Davis KL, Haroutunian V. Large-scale microarray studies of gene expression in multiple regions of the brain in schizophrenia and Alzheimer's disease. Int Rev Neurobiol. 2005; 63:41-82.
      View in: PubMed
    132. Brown AM, Gordon D, Lee H, Caudy M, Hardy J, Haroutunian V, Blass JP. Association of the dihydrolipoamide dehydrogenase gene with Alzheimer's disease in an Ashkenazi Jewish population. Am J Med Genet B Neuropsychiatr Genet. 2004 Nov 15; 131B(1):60-6.
      View in: PubMed
    133. Buckland PR, Hoogendoorn B, Guy CA, Coleman SL, Smith SK, Buxbaum JD, Haroutunian V, O'Donovan MC. A high proportion of polymorphisms in the promoters of brain expressed genes influences transcriptional activity. Biochim Biophys Acta. 2004 Nov 5; 1690(3):238-49.
      View in: PubMed
    134. Cataldo AM, Petanceska S, Terio NB, Peterhoff CM, Durham R, Mercken M, Mehta PD, Buxbaum J, Haroutunian V, Nixon RA. Abeta localization in abnormal endosomes: association with earliest Abeta elevations in AD and Down syndrome. Neurobiol Aging. 2004 Nov-Dec; 25(10):1263-72.
      View in: PubMed
    135. Gordon D, Yang Y, Haynes C, Finch SJ, Mendell NR, Brown AM, Haroutunian V. Increasing power for tests of genetic association in the presence of phenotype and/or genotype error by use of double-sampling. Stat Appl Genet Mol Biol. 2004; 3:Article26.
      View in: PubMed
    136. Bray NJ, Jehu L, Moskvina V, Buxbaum JD, Dracheva S, Haroutunian V, Williams J, Buckland PR, Owen MJ, O'Donovan MC. Allelic expression of APOE in human brain: effects of epsilon status and promoter haplotypes. Hum Mol Genet. 2004 Nov 15; 13(22):2885-92.
      View in: PubMed
    137. Bai J, He F, Novikova SI, Undie AS, Dracheva S, Haroutunian V, Lidow MS. Abnormalities in the dopamine system in schizophrenia may lie in altered levels of dopamine receptor-interacting proteins. Biol Psychiatry. 2004 Sep 15; 56(6):427-40.
      View in: PubMed
    138. Wen PH, Hof PR, Chen X, Gluck K, Austin G, Younkin SG, Younkin LH, DeGasperi R, Gama Sosa MA, Robakis NK, Haroutunian V, Elder GA. The presenilin-1 familial Alzheimer disease mutant P117L impairs neurogenesis in the hippocampus of adult mice. Exp Neurol. 2004 Aug; 188(2):224-37.
      View in: PubMed
    139. Dracheva S, Elhakem SL, McGurk SR, Davis KL, Haroutunian V. GAD67 and GAD65 mRNA and protein expression in cerebrocortical regions of elderly patients with schizophrenia. J Neurosci Res. 2004 May 15; 76(4):581-92.
      View in: PubMed
    140. Brown AM, Gordon D, Lee H, Caudy M, Haroutunian V, Blass JP. Substantial linkage disequilibrium across the dihydrolipoyl succinyltransferase gene region without Alzheimer's disease association. Neurochem Res. 2004 Mar; 29(3):629-35.
      View in: PubMed
    141. Mueller HT, Haroutunian V, Davis KL, Meador-Woodruff JH. Expression of the ionotropic glutamate receptor subunits and NMDA receptor-associated intracellular proteins in the substantia nigra in schizophrenia. Brain Res Mol Brain Res. 2004 Feb 5; 121(1-2):60-9.
      View in: PubMed
    142. Bubber P, Tang J, Haroutunian V, Xu H, Davis KL, Blass JP, Gibson GE. Mitochondrial enzymes in schizophrenia. J Mol Neurosci. 2004; 24(2):315-21.
      View in: PubMed
    143. Santucci AC, Haroutunian V. p-Chloroamphetamine blocks physostigmine-induced memory enhancement in rats with unilateral nucleus basalis lesions. Pharmacol Biochem Behav. 2004 Jan; 77(1):59-67.
      View in: PubMed
    144. Martin-Ruiz CM, Haroutunian VH, Long P, Young AH, Davis KL, Perry EK, Court JA. Dementia rating and nicotinic receptor expression in the prefrontal cortex in schizophrenia. Biol Psychiatry. 2003 Dec 1; 54(11):1222-33.
      View in: PubMed
    145. Dracheva S, Elhakem SL, Marcus SM, Siever LJ, McGurk SR, Haroutunian V. RNA editing and alternative splicing of human serotonin 2C receptor in schizophrenia. J Neurochem. 2003 Dec; 87(6):1402-12.
      View in: PubMed
    146. Halks-Miller M, Schroeder ML, Haroutunian V, Moenning U, Rossi M, Achim C, Purohit D, Mahmoudi M, Horuk R. CCR1 is an early and specific marker of Alzheimer's disease. Ann Neurol. 2003 Nov; 54(5):638-46.
      View in: PubMed
    147. Lilliehook C, Bozdagi O, Yao J, Gomez-Ramirez M, Zaidi NF, Wasco W, Gandy S, Santucci AC, Haroutunian V, Huntley GW, Buxbaum JD. Altered Abeta formation and long-term potentiation in a calsenilin knock-out. J Neurosci. 2003 Oct 8; 23(27):9097-106.
      View in: PubMed
    148. Causevic M, Ramoz N, Haroutunian V, Davis KL, Buxbaum JD. Lack of association between the levels of the low-density lipoprotein receptor-related protein (LRP) and either Alzheimer dementia or LRP exon 3 genotype. J Neuropathol Exp Neurol. 2003 Oct; 62(10):999-1005.
      View in: PubMed
    149. Polesskaya OO, Haroutunian V, Davis KL, Hernandez I, Sokolov BP. Novel putative nonprotein-coding RNA gene from 11q14 displays decreased expression in brains of patients with schizophrenia. J Neurosci Res. 2003 Oct 1; 74(1):111-22.
      View in: PubMed
    150. Davis KL, Haroutunian V. Global expression-profiling studies and oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet. 2003 Sep 6; 362(9386):758.
      View in: PubMed
    151. Hof PR, Haroutunian V, Friedrich VL, Byne W, Buitron C, Perl DP, Davis KL. Loss and altered spatial distribution of oligodendrocytes in the superior frontal gyrus in schizophrenia. Biol Psychiatry. 2003 Jun 15; 53(12):1075-85.
      View in: PubMed
    152. Clinton SM, Haroutunian V, Davis KL, Meador-Woodruff JH. Altered transcript expression of NMDA receptor-associated postsynaptic proteins in the thalamus of subjects with schizophrenia. Am J Psychiatry. 2003 Jun; 160(6):1100-9.
      View in: PubMed
    153. Religa D, Laudon H, Styczynska M, Winblad B, Näslund J, Haroutunian V. Amyloid beta pathology in Alzheimer's disease and schizophrenia. Am J Psychiatry. 2003 May; 160(5):867-72.
      View in: PubMed
    154. Davis KL, Stewart DG, Friedman JI, Buchsbaum M, Harvey PD, Hof PR, Buxbaum J, Haroutunian V. White matter changes in schizophrenia: evidence for myelin-related dysfunction. Arch Gen Psychiatry. 2003 May; 60(5):443-56.
      View in: PubMed
    155. Serby M, Brickman AM, Haroutunian V, Purohit DP, Marin D, Lantz M, Mohs RC, Davis KL. Cognitive burden and excess Lewy-body pathology in the Lewy-body variant of Alzheimer disease. Am J Geriatr Psychiatry. 2003 May-Jun; 11(3):371-4.
      View in: PubMed
    156. Utsuki T, Shoaib M, Holloway HW, Ingram DK, Wallace WC, Haroutunian V, Sambamurti K, Lahiri DK, Greig NH. Nicotine lowers the secretion of the Alzheimer's amyloid beta-protein precursor that contains amyloid beta-peptide in rat. J Alzheimers Dis. 2002 Oct; 4(5):405-15.
      View in: PubMed
    157. Hof PR, Haroutunian V, Copland C, Davis KL, Buxbaum JD. Molecular and cellular evidence for an oligodendrocyte abnormality in schizophrenia. Neurochem Res. 2002 Oct; 27(10):1193-200.
      View in: PubMed
    158. Haroutunian V, Davis KL. Issues and perspectives on brain tissue banking. Curr Psychiatry Rep. 2002 Aug; 4(4):233-4.
      View in: PubMed
    159. Gluck MR, Thomas RG, Davis KL, Haroutunian V. Implications for altered glutamate and GABA metabolism in the dorsolateral prefrontal cortex of aged schizophrenic patients. Am J Psychiatry. 2002 Jul; 159(7):1165-73.
      View in: PubMed
    160. Byne W, Buchsbaum MS, Mattiace LA, Hazlett EA, Kemether E, Elhakem SL, Purohit DP, Haroutunian V, Jones L. Postmortem assessment of thalamic nuclear volumes in subjects with schizophrenia. Am J Psychiatry. 2002 Jan; 159(1):59-65.
      View in: PubMed
    161. Parvathy S, Davies P, Haroutunian V, Purohit DP, Davis KL, Mohs RC, Park H, Moran TM, Chan JY, Buxbaum JD. Correlation between Abetax-40-, Abetax-42-, and Abetax-43-containing amyloid plaques and cognitive decline. Arch Neurol. 2001 Dec; 58(12):2025-32.
      View in: PubMed
    162. Smith RE, Haroutunian V, Davis KL, Meador-Woodruff JH. Vesicular glutamate transporter transcript expression in the thalamus in schizophrenia. Neuroreport. 2001 Sep 17; 12(13):2885-7.
      View in: PubMed
    163. Smith RE, Haroutunian V, Davis KL, Meador-Woodruff JH. Expression of excitatory amino acid transporter transcripts in the thalamus of subjects with schizophrenia. Am J Psychiatry. 2001 Sep; 158(9):1393-9.
      View in: PubMed
    164. Dracheva S, Marras SA, Elhakem SL, Kramer FR, Davis KL, Haroutunian V. N-methyl-D-aspartic acid receptor expression in the dorsolateral prefrontal cortex of elderly patients with schizophrenia. Am J Psychiatry. 2001 Sep; 158(9):1400-10.
      View in: PubMed
    165. Dracheva S, Haroutunian V. Locomotor behavior of dopamine D1 receptor transgenic/D2 receptor deficient hybrid mice. Brain Res. 2001 Jun 29; 905(1-2):142-51.
      View in: PubMed
    166. Meador-Woodruff JH, Davis KL, Haroutunian V. Abnormal kainate receptor expression in prefrontal cortex in schizophrenia. Neuropsychopharmacology. 2001 May; 24(5):545-52.
      View in: PubMed
    167. Hakak Y, Walker JR, Li C, Wong WH, Davis KL, Buxbaum JD, Haroutunian V, Fienberg AA. Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc Natl Acad Sci U S A. 2001 Apr 10; 98(8):4746-51.
      View in: PubMed
    168. Lesser G, Kandiah K, Libow LS, Likourezos A, Breuer B, Marin D, Mohs R, Haroutunian V, Neufeld R. Elevated serum total and LDL cholesterol in very old patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 2001 Mar-Apr; 12(2):138-45.
      View in: PubMed
    169. Ho L, Purohit D, Haroutunian V, Luterman JD, Willis F, Naslund J, Buxbaum JD, Mohs RC, Aisen PS, Pasinetti GM. Neuronal cyclooxygenase 2 expression in the hippocampal formation as a function of the clinical progression of Alzheimer disease. Arch Neurol. 2001 Mar; 58(3):487-92.
      View in: PubMed
    170. Ho L, Guo Y, Spielman L, Petrescu O, Haroutunian V, Purohit D, Czernik A, Yemul S, Aisen PS, Mohs R, Pasinetti GM. Altered expression of a-type but not b-type synapsin isoform in the brain of patients at high risk for Alzheimer's disease assessed by DNA microarray technique. Neurosci Lett. 2001 Feb 9; 298(3):191-4.
      View in: PubMed
    171. Brown AM, Sheu RK, Mohs R, Haroutunian V, Blass JP. Correlation of the clinical severity of Alzheimer's disease with an aberration in mitochondrial DNA (mtDNA). J Mol Neurosci. 2001 Feb; 16(1):41-8.
      View in: PubMed
    172. Ibrahim HM, Hogg AJ, Healy DJ, Haroutunian V, Davis KL, Meador-Woodruff JH. Ionotropic glutamate receptor binding and subunit mRNA expression in thalamic nuclei in schizophrenia. Am J Psychiatry. 2000 Nov; 157(11):1811-23.
      View in: PubMed
    173. Gibson GE, Haroutunian V, Zhang H, Park LC, Shi Q, Lesser M, Mohs RC, Sheu RK, Blass JP. Mitochondrial damage in Alzheimer's disease varies with apolipoprotein E genotype. Ann Neurol. 2000 Sep; 48(3):297-303.
      View in: PubMed
    174. Luterman JD, Haroutunian V, Yemul S, Ho L, Purohit D, Aisen PS, Mohs R, Pasinetti GM. Cytokine gene expression as a function of the clinical progression of Alzheimer disease dementia. Arch Neurol. 2000 Aug; 57(8):1153-60.
      View in: PubMed
    175. Haroutunian V, Serby M, Purohit DP, Perl DP, Marin D, Lantz M, Mohs RC, Davis KL. Contribution of Lewy body inclusions to dementia in patients with and without Alzheimer disease neuropathological conditions. Arch Neurol. 2000 Aug; 57(8):1145-50.
      View in: PubMed
    176. Sokolov BP, Tcherepanov AA, Haroutunian V, Davis KL. Levels of mRNAs encoding synaptic vesicle and synaptic plasma membrane proteins in the temporal cortex of elderly schizophrenic patients. Biol Psychiatry. 2000 Aug 1; 48(3):184-96.
      View in: PubMed
    177. Harvey PD, Jacobsen H, Mancini D, Parrella M, White L, Haroutunian V, Davis KL. Clinical, cognitive and functional characteristics of long-stay patients with schizophrenia: a comparison of VA and state hospital patients. Schizophr Res. 2000 May 25; 43(1):3-9.
      View in: PubMed
    178. Perry E, Martin-Ruiz C, Lee M, Griffiths M, Johnson M, Piggott M, Haroutunian V, Buxbaum JD, Nãsland J, Davis K, Gotti C, Clementi F, Tzartos S, Cohen O, Soreq H, Jaros E, Perry R, Ballard C, McKeith I, Court J. Nicotinic receptor subtypes in human brain ageing, Alzheimer and Lewy body diseases. Eur J Pharmacol. 2000 Mar 30; 393(1-3):215-22.
      View in: PubMed
    179. Näslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, Buxbaum JD. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA. 2000 Mar 22-29; 283(12):1571-7.
      View in: PubMed
    180. Gluck MR, Jayatilleke E, Shaw S, Rowan AJ, Haroutunian V. CNS oxidative stress associated with the kainic acid rodent model of experimental epilepsy. Epilepsy Res. 2000 Mar; 39(1):63-71.
      View in: PubMed
    181. Gouras GK, Tsai J, Naslund J, Vincent B, Edgar M, Checler F, Greenfield JP, Haroutunian V, Buxbaum JD, Xu H, Greengard P, Relkin NR. Intraneuronal Abeta42 accumulation in human brain. Am J Pathol. 2000 Jan; 156(1):15-20.
      View in: PubMed
    182. Richardson-Burns SM, Haroutunian V, Davis KL, Watson SJ, Meador-Woodruff JH. Metabotropic glutamate receptor mRNA expression in the schizophrenic thalamus. Biol Psychiatry. 2000 Jan 1; 47(1):22-8.
      View in: PubMed
    183. Davis KL, Mohs RC, Marin DB, Purohit DP, Perl DP, Lantz M, Austin G, Haroutunian V. Neuropeptide abnormalities in patients with early Alzheimer disease. Arch Gen Psychiatry. 1999 Nov; 56(11):981-7.
      View in: PubMed
    184. Haroutunian V, Purohit DP, Perl DP, Marin D, Khan K, Lantz M, Davis KL, Mohs RC. Neurofibrillary tangles in nondemented elderly subjects and mild Alzheimer disease. Arch Neurol. 1999 Jun; 56(6):713-8.
      View in: PubMed
    185. Dracheva S, Xu M, Kelley KA, Haroutunian V, Holstein GR, Haun S, Silverstein JH, Sealfon SC. Paradoxical locomotor behavior of dopamine D1 receptor transgenic mice. Exp Neurol. 1999 May; 157(1):169-79.
      View in: PubMed
    186. Davis KL, Mohs RC, Marin D, Purohit DP, Perl DP, Lantz M, Austin G, Haroutunian V. Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA. 1999 Apr 21; 281(15):1401-6.
      View in: PubMed
    187. Kaplan B, Haroutunian V, Koudinov A, Patael Y, Pras M, Gallo G. Biochemical assay for amyloid beta deposits to distinguish Alzheimer's disease from other dementias. Clin Chim Acta. 1999 Feb; 280(1-2):147-59.
      View in: PubMed
    188. Sheu KF, Brown AM, Haroutunian V, Kristal BS, Thaler H, Lesser M, Kalaria RN, Relkin NR, Mohs RC, Lilius L, Lannfelt L, Blass JP. Modulation by DLST of the genetic risk of Alzheimer's disease in a very elderly population. Ann Neurol. 1999 Jan; 45(1):48-53.
      View in: PubMed
    189. Healy DJ, Haroutunian V, Powchik P, Davidson M, Davis KL, Watson SJ, Meador-Woodruff JH. AMPA receptor binding and subunit mRNA expression in prefrontal cortex and striatum of elderly schizophrenics. Neuropsychopharmacology. 1998 Oct; 19(4):278-86.
      View in: PubMed
    190. Shimon H, Sobolev Y, Davidson M, Haroutunian V, Belmaker RH, Agam G. Inositol levels are decreased in postmortem brain of schizophrenic patients. Biol Psychiatry. 1998 Sep 15; 44(6):428-32.
      View in: PubMed
    191. Haroutunian V, Perl DP, Purohit DP, Marin D, Khan K, Lantz M, Davis KL, Mohs RC. Regional distribution of neuritic plaques in the nondemented elderly and subjects with very mild Alzheimer disease. Arch Neurol. 1998 Sep; 55(9):1185-91.
      View in: PubMed
    192. Purohit DP, Perl DP, Haroutunian V, Powchik P, Davidson M, Davis KL. Alzheimer disease and related neurodegenerative diseases in elderly patients with schizophrenia: a postmortem neuropathologic study of 100 cases. Arch Gen Psychiatry. 1998 Mar; 55(3):205-11.
      View in: PubMed
    193. Powchik P, Davidson M, Haroutunian V, Gabriel SM, Purohit DP, Perl DP, Harvey PD, Davis KL. Postmortem studies in schizophrenia. Schizophr Bull. 1998; 24(3):325-41.
      View in: PubMed
    194. Reznik-Wolf H, Machado J, Haroutunian V, DeMarco L, Walter GF, Goldman B, Davidson M, Johnston JA, Lannfelt L, Dani SU, Friedman E. Somatic mutation analysis of the APP and Presenilin 1 and 2 genes in Alzheimer's disease brains. J Neurogenet. 1998 Jan; 12(1):55-65.
      View in: PubMed
    195. Meador-Woodruff JH, Haroutunian V, Powchik P, Davidson M, Davis KL, Watson SJ. Dopamine receptor transcript expression in striatum and prefrontal and occipital cortex. Focal abnormalities in orbitofrontal cortex in schizophrenia. Arch Gen Psychiatry. 1997 Dec; 54(12):1089-95.
      View in: PubMed
    196. Powchik P, Friedman J, Haroutunian V, Greenberg D, Altsteil L, Purohit D, Perl D, Davidson M. Apolipoprotein E4 in schizophrenia: a study of one hundred sixteen cases with concomitant neuropathological examination. Biol Psychiatry. 1997 Aug 15; 42(4):296-8.
      View in: PubMed
    197. Haroutunian V, Greig N, Pei XF, Utsuki T, Gluck R, Acevedo LD, Davis KL, Wallace WC. Pharmacological modulation of Alzheimer's beta-amyloid precursor protein levels in the CSF of rats with forebrain cholinergic system lesions. Brain Res Mol Brain Res. 1997 Jun; 46(1-2):161-8.
      View in: PubMed
    198. Gabriel SM, Haroutunian V, Powchik P, Honer WG, Davidson M, Davies P, Davis KL. Increased concentrations of presynaptic proteins in the cingulate cortex of subjects with schizophrenia. Arch Gen Psychiatry. 1997 Jun; 54(6):559-66.
      View in: PubMed
    199. Li G, Aryan M, Silverman JM, Haroutunian V, Perl DP, Birstein S, Lantz M, Marin DB, Mohs RC, Davis KL. The validity of the family history method for identifying Alzheimer disease. Arch Neurol. 1997 May; 54(5):634-40.
      View in: PubMed
    200. Haroutunian V, Zhou Y, Elder G, Li C, Lazzarini RA. Age-dependent spatial memory deficits in transgenic mice expressing the human mid-sized neurofilament gene: I. Brain Res Mol Brain Res. 1996 Nov; 42(1):62-70.
      View in: PubMed
    201. Meador-Woodruff JH, Damask SP, Wang J, Haroutunian V, Davis KL, Watson SJ. Dopamine receptor mRNA expression in human striatum and neocortex. Neuropsychopharmacology. 1996 Jul; 15(1):17-29.
      View in: PubMed
    202. Klein JT, Davis L, Olsen GE, Wong GS, Huger FP, Smith CP, Petko WW, Cornfeldt M, Wilker JC, Blitzer RD, Landau E, Haroutunian V, Martin LL, Effland RC. Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeutic agents for Alzheimer's disease. J Med Chem. 1996 Jan 19; 39(2):570-81.
      View in: PubMed
    203. Gabriel SM, Davidson M, Haroutunian V, Powchik P, Bierer LM, Purohit DP, Perl DP, Davis KL. Neuropeptide deficits in schizophrenia vs. Alzheimer's disease cerebral cortex. Biol Psychiatry. 1996 Jan 15; 39(2):82-91.
      View in: PubMed
    204. Santucci AC, Knott PJ, Haroutunian V. Excessive serotonin release, not depletion, leads to memory impairments in rats. Eur J Pharmacol. 1996 Jan 4; 295(1):7-17.
      View in: PubMed
    205. Li G, Silverman JM, Altstiel LD, Haroutunian V, Perl DP, Purohit D, Birstein S, Lantz M, Mohs RC, Davis KL. Apolipoprotein E-epsilon 4 allele and familial risk in Alzheimer's disease. Genet Epidemiol. 1996; 13(3):285-98.
      View in: PubMed
    206. Gabriel SM, Knott PJ, Haroutunian V. Alterations in cerebral cortical galanin concentrations following neurotransmitter-specific subcortical lesions in the rat. J Neurosci. 1995 Aug; 15(8):5526-34.
      View in: PubMed
    207. Santucci AC, Kanof PD, Haroutunian V. Transient enhancement of cholinergic neurochemical markers induced by NGF in aged F344 rats. Dementia. 1995 Jul-Aug; 6(4):179-84.
      View in: PubMed
    208. Wallace WC, Lieberburg I, Schenk D, Vigo-Pelfrey C, Davis KL, Haroutunian V. Chronic elevation of secreted amyloid precursor protein in subcortically lesioned rats, and its exacerbation in aged rats. J Neurosci. 1995 Jul; 15(7 Pt 1):4896-905.
      View in: PubMed
    209. Lawlor BA, Ryan TM, Bierer LM, Schmeidler J, Haroutunian V, Mohs R, Davis KL. Lack of association between clinical symptoms and postmortem indices of brain serotonin function in Alzheimer's disease. Biol Psychiatry. 1995 Jun 15; 37(12):895-6.
      View in: PubMed
    210. Bierer LM, Haroutunian V, Gabriel S, Knott PJ, Carlin LS, Purohit DP, Perl DP, Schmeidler J, Kanof P, Davis KL. Neurochemical correlates of dementia severity in Alzheimer's disease: relative importance of the cholinergic deficits. J Neurochem. 1995 Feb; 64(2):749-60.
      View in: PubMed
    211. Miller M, Haroutunian V, Wiltshire-Clement M. Altered alertness of vasopressin-secreting transgenic mice. Peptides. 1995; 16(8):1329-33.
      View in: PubMed
    212. Haroutunian V, Davidson M, Kanof PD, Perl DP, Powchik P, Losonczy M, McCrystal J, Purohit DP, Bierer LM, Davis KL. Cortical cholinergic markers in schizophrenia. Schizophr Res. 1994 May; 12(2):137-44.
      View in: PubMed
    213. Perry EK, Haroutunian V, Davis KL, Levy R, Lantos P, Eagger S, Honavar M, Dean A, Griffiths M, McKeith IG, et al. Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer's disease. Neuroreport. 1994 Mar 21; 5(7):747-9.
      View in: PubMed
    214. Wallace W, Brane D, Hsu N, Khowong N, Merril CR, Haroutunian V. Characterization of gene expression in the cerebral cortices of rat brains containing subcortical lesions. Appl Theor Electrophor. 1994; 4(1):33-8.
      View in: PubMed
    215. Bierer LM, Knott PJ, Schmeidler JM, Marin DB, Ryan TM, Haroutunian V, Purohit DP, Perl DP, Mohs RC, Davis KL. Post-mortem examination of dopaminergic parameters in Alzheimer's disease: relationship to noncognitive symptoms. Psychiatry Res. 1993 Dec; 49(3):211-7.
      View in: PubMed
    216. Wallace W, Haroutunian V. Using the subcortically lesioned rat cortex to understand the physiological role of amyloid precursor protein. Behav Brain Res. 1993 Nov 30; 57(2):199-206.
      View in: PubMed
    217. Powchik P, Davidson M, Nemeroff CB, Haroutunian V, Purohit D, Losonczy M, Bissette G, Perl D, Ghanbari H, Miller B, et al. Alzheimer's-disease-related protein in geriatric schizophrenic patients with cognitive impairment. Am J Psychiatry. 1993 Nov; 150(11):1726-7.
      View in: PubMed
    218. Schmauss C, Haroutunian V, Davis KL, Davidson M. Selective loss of dopamine D3-type receptor mRNA expression in parietal and motor cortices of patients with chronic schizophrenia. Proc Natl Acad Sci U S A. 1993 Oct 1; 90(19):8942-6.
      View in: PubMed
    219. Wallace W, Ahlers ST, Gotlib J, Bragin V, Sugar J, Gluck R, Shea PA, Davis KL, Haroutunian V. Amyloid precursor protein in the cerebral cortex is rapidly and persistently induced by loss of subcortical innervation. Proc Natl Acad Sci U S A. 1993 Sep 15; 90(18):8712-6.
      View in: PubMed
    220. Santucci AC, Gluck R, Kanof PD, Haroutunian V. Induction of memory and cortical cholinergic neurochemical recovery with combine fetal transplantation and GM1 treatments in rats with lesions of the NBM. Dementia. 1993 Sep-Oct; 4(5):273-81.
      View in: PubMed
    221. Santucci AC, Kanof PD, Haroutunian V. Cholinergic marker deficits induced by lesions of the nucleus basalis of Meynert are attenuated by nerve growth factor in young, but not in aged, F344 rats. Brain Res. 1993 Apr 23; 609(1-2):327-32.
      View in: PubMed
    222. Purohit DP, Davidson M, Perl DP, Powchik P, Haroutunian VH, Bierer LM, McCrystal J, Losonczy M, Davis KL. Severe cognitive impairment in elderly schizophrenic patients: a clinicopathological study. Biol Psychiatry. 1993 Feb 15; 33(4):255-60.
      View in: PubMed
    223. Johnson G, Gotlib J, Haroutunian V, Bierer L, Nairn AC, Merril C, Wallace W. Increased phosphorylation of elongation factor 2 in Alzheimer's disease. Brain Res Mol Brain Res. 1992 Oct; 15(3-4):319-26.
      View in: PubMed
    224. Perez N, Sugar J, Charya S, Johnson G, Merril C, Bierer L, Perl D, Haroutunian V, Wallace W. Increased synthesis and accumulation of heat shock 70 proteins in Alzheimer's disease. Brain Res Mol Brain Res. 1991 Oct; 11(3-4):249-54.
      View in: PubMed
    225. Wallace WC, Bragin V, Robakis NK, Sambamurti K, VanderPutten D, Merril CR, Davis KL, Santucci AC, Haroutunian V. Increased biosynthesis of Alzheimer amyloid precursor protein in the cerebral cortex of rats with lesions of the nucleus basalis of Meynert. Brain Res Mol Brain Res. 1991 May; 10(2):173-8.
      View in: PubMed
    226. Santucci AC, Kanof PD, Haroutunian V. Fetal transplant-induced restoration of spatial memory in rats with lesions of the nucleus basalis of Meynert. J Neural Transplant Plast. 1991; 2(1):65-74.
      View in: PubMed
    227. Parks KM, Sugar JE, Haroutunian V, Bierer L, Perl D, Wallace WC. Reduced in vitro phosphorylation of synapsin I (site 1) in Alzheimer's disease postmortem tissues. Brain Res Mol Brain Res. 1991 Jan; 9(1-2):125-34.
      View in: PubMed
    228. Santucci AC, Haroutunian V, Davis KL. Pharmacological alleviation of combined cholinergic/noradrenergic lesion-induced memory deficits in rats. Clin Neuropharmacol. 1991; 14 Suppl 1:S1-8.
      View in: PubMed
    229. Haroutunian V, Kanof PD, Tsuboyama G, Davis KL. Restoration of cholinomimetic activity by clonidine in cholinergic plus noradrenergic lesioned rats. Brain Res. 1990 Jan 22; 507(2):261-6.
      View in: PubMed
    230. Bierer LM, Perl DP, Haroutunian V, Mohs RC, Davis KL. Neurofibrillary tangles, Alzheimer's disease and Lewy bodies. Lancet. 1990 Jan 20; 335(8682):163.
      View in: PubMed
    231. Haroutunian V, Santucci AC, Davis KL. Implications of multiple transmitter system lesions for cholinomimetic therapy in Alzheimer's disease. Prog Brain Res. 1990; 84:333-46.
      View in: PubMed
    232. Haroutunian V, Mantin R, Kanof PD. Frontal cortex as the site of action of physostigmine in nbM-lesioned rats. Physiol Behav. 1990 Jan; 47(1):203-6.
      View in: PubMed
    233. Anderson JP, Refolo LM, Wallace W, Mehta P, Krishnamurthi M, Gotlib J, Bierer L, Haroutunian V, Perl D, Robakis NK. Differential brain expression of the Alzheimer's amyloid precursor protein. EMBO J. 1989 Dec 1; 8(12):3627-32.
      View in: PubMed
    234. Haroutunian V, Kanof PD, Davis KL. Interactions of forebrain cholinergic and somatostatinergic systems in the rat. Brain Res. 1989 Sep 4; 496(1-2):98-104.
      View in: PubMed
    235. Shutske GM, Pierrat FA, Kapples KJ, Cornfeldt ML, Szewczak MR, Huger FP, Bores GM, Haroutunian V, Davis KL. 9-Amino-1,2,3,4-tetrahydroacridin-1-ols: synthesis and evaluation as potential Alzheimer's disease therapeutics. J Med Chem. 1989 Aug; 32(8):1805-13.
      View in: PubMed
    236. Santucci AC, Kanof PD, Haroutunian V. Infusion of NMDA into the nucleus basalis of Meynert, frontal cortex or lateral ventricle in rats: effect on memory and cholinergic brain neurochemistry. Pharmacol Biochem Behav. 1989 Jun; 33(2):485-8.
      View in: PubMed
    237. Haroutunian V, Kanof PD, Davis KL. Attenuation of nucleus basalis of Meynert lesion-induced cholinergic deficits by nerve growth factor. Brain Res. 1989 May 15; 487(1):200-3.
      View in: PubMed
    238. Santucci AC, Haroutunian V. Nucleus basalis lesions impair memory in rats trained on nonspatial and spatial discrimination tasks. Physiol Behav. 1989 May; 45(5):1025-31.
      View in: PubMed
    239. Benson DM, Blitzer RD, Haroutunian V, Landau EM. Functional muscarinic supersensitivity in denervated rat hippocampus. Brain Res. 1989 Jan 30; 478(2):399-402.
      View in: PubMed
    240. Anderson J, Wallace W, Snyder S, Haroutunian V, Roberts JL, Lieberburg I. Cellular forms of the rat and human beta-amyloid precursor protein (BAPP). Brain Res. 1989 Jan 30; 478(2):391-8.
      View in: PubMed
    241. Santucci AC, Kanof PD, Haroutunian V. Effect of physostigmine on memory consolidation and retrieval processes in intact and nucleus basalis-lesioned rats. Psychopharmacology (Berl). 1989; 99(1):70-4.
      View in: PubMed
    242. Santucci AC, Haroutunian V, Tsuboyama GK, Kanof PD, Davis KL. Therapeutics of Alzheimer's disease for clinical and pre-clinical issues. Prog Clin Biol Res. 1989; 317:1111-20.
      View in: PubMed
    243. Shutske GM, Pierrat FA, Cornfeldt ML, Szewczak MR, Huger FP, Bores GM, Haroutunian V, Davis KL. (+/-)-9-Amino-1,2,3,4-tetrahydroacridin-1-ol. A potential Alzheimer's disease therapeutic of low toxicity. J Med Chem. 1988 Jul; 31(7):1278-9.
      View in: PubMed
    244. Haroutunian V, Knott P, Davis KL. Effects of mesocortical dopaminergic lesions upon subcortical dopaminergic function. Psychopharmacol Bull. 1988; 24(3):341-4.
      View in: PubMed
    245. Haroutunian V, Mantin R, Campbell GA, Tsuboyama GK, Davis KL. Cysteamine-induced depletion of central somatostatin-like immunoactivity: effects on behavior, learning, memory and brain neurochemistry. Brain Res. 1987 Feb 17; 403(2):234-42.
      View in: PubMed
    246. Haroutunian V, Kanof PD, Tsuboyama GK, Campbell GA, Davis KL. Animal models of Alzheimer's disease: behavior, pharmacology, transplants. Can J Neurol Sci. 1986 Nov; 13(4 Suppl):385-93.
      View in: PubMed
    247. Haroutunian V, Kanof PD, Davis KL. Partial reversal of lesion-induced deficits in cortical cholinergic markers by nerve growth factor. Brain Res. 1986 Oct 29; 386(1-2):397-9.
      View in: PubMed
    248. Haroutunian V, Kanof P, Davis KL. Pharmacological alleviation of cholinergic lesion induced memory deficits in rats. Life Sci. 1985 Sep 9; 37(10):945-52.
      View in: PubMed
    249. Haroutunian V, Barnes E, Davis KL. Cholinergic modulation of memory in rats. Psychopharmacology (Berl). 1985; 87(3):266-71.
      View in: PubMed
    250. Campbell BA, Haroutunian V. Perceptual sharpening in the developing rat. J Comp Psychol. 1983 Mar; 97(1):3-11.
      View in: PubMed
    251. Haroutunian V, Campbell BA. Neural control of the heart-rate-orienting response in preweanling rats. Behav Neural Biol. 1982 Sep; 36(1):24-39.
      View in: PubMed
    252. Campbell BA, Haroutunian V. Effects of age on long-term memory: retention of fixed interval responding. J Gerontol. 1981 May; 36(3):338-41.
      View in: PubMed
    253. Haroutunian V, Campbell BA. Development and habituation of the heart rate orienting response to auditory and visual stimuli in the rat. J Comp Physiol Psychol. 1981 Feb; 95(1):166-74.
      View in: PubMed
    254. Stehouwer DJ, Haroutunian V, Campbell BA. Generalization of habituation to electrical stimulation of the forelimb in neonatal and preweanling rats. Behav Neural Biol. 1980 Jun; 29(2):203-15.
      View in: PubMed
    255. Haroutunian V, Campbell BA. Emergence of interoceptive and exteroceptive control of behavior in rats. Science. 1979 Aug 31; 205(4409):927-9.
      View in: PubMed
    256. Haroutunian V, Riccio DC. Reduction of ontogenetic retention decrements in rats by pretraining stressful experiences. J Comp Physiol Psychol. 1979 Jun; 93(3):501-11.
      View in: PubMed
    257. Haroutunian V, Riccio DC. Age-dependent effects of preconditioning aversive experiences on the retention of conditioned fear in weanling rats. Behav Neural Biol. 1979 Jun; 26(2):248-53.
      View in: PubMed
    258. Haroutunian V, Riccio DC. Drug-induced "arousal" and the effectiveness of CS exposure in the reinstatement of memory. Behav Neural Biol. 1979 May; 26(1):115-20.
      View in: PubMed
    259. Haroutunian V, Riccio DC. Effect of arousal conditions during reinstatement treatment upon learned fear in young rats. Dev Psychobiol. 1977 Jan; 10(1):25-32.
      View in: PubMed
    Haroutunian's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts
    _
    Co-Authors
    _
    Similar People
    _
    Same Department
     
    Mount Sinai Profiles is managed by Conduits - The Institutes for Translational Sciences at Icahn School of Medicine, supported by the National Center for Research Resources and the National Center for Advancing Translational Sciences of the National Institutes of Health through Grant Number UL1TR000067